Mixed Phase II Results With Isis-CRPRx in RA Patients

A Phase II study of patients with rheumatoid arthritis, conducted by Isis Pharmaceuticals, showed that patients treated with Isis-CRPRx showed a 67 percent decrease in C-reactive protein.
The Pharma Letter